Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 22 tags : Vaccine save search
Vaxart To Present at Upcoming Vaccine Conferences
Published: 2021-09-22 (Crawled : 00:00) - biospace.com/
VXRT | News | $0.7422 -2.66% -2.74% 1.5M
|
Health Technology
|
| O: 0.87%
H: 1.96%
C: 0.49%
vaccine conference presentation
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
Published: 2021-09-22 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
covid expansion collaboration vaccine ceo
National Survey: “Trust” at the Heart of Low U.S. Vaccination Rates
Published: 2021-09-22 (Crawled : 16:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
heart vaccine
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO | $10.34 3.19% 3.09% 240K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
DVAX | $11.75 -0.76% -0.77% 1.4M
|
Health Technology
|
| O: 6.33%
H: 30.76%
C: 18.92%
covid phase 2 phase 2/3 vaccine trial
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
Published: 2021-09-22 (Crawled : 11:00) - prnewswire.com
DVAX | $11.75 -0.76% -0.77% 1.4M
|
Health Technology
|
| O: 6.33%
H: 30.76%
C: 18.92%
covid phase 2 biopharma phase 2/3 vaccine trial
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
Published: 2021-09-22 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.89%
H: 0.16%
C: -0.35%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 0.43%
H: 0.52%
C: -1.03%
covid collaboration vaccine
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.